Targeting Glioblastoma via Selective Alteration of Mitochondrial Redox State
Open Access
- 19 January 2022
- Vol. 14 (3), 485
- https://doi.org/10.3390/cancers14030485
Abstract
Glioblastoma is one of the most aggressive brain tumors, characterized by a pronounced redox imbalance, expressed in a high oxidative capacity of cancer cells due to their elevated glycolytic and mitochondrial oxidative metabolism. The assessment and modulation of the redox state of glioblastoma are crucial factors that can provide highly specific targeting and treatment. Our study describes a pharmacological strategy for targeting glioblastoma using a redox-active combination drug. The experiments were conducted in vivo on glioblastoma mice (intracranial model) and in vitro on cell lines (cancer and normal) treated with the redox cycling pair menadione/ascorbate (M/A). The following parameters were analyzed in vivo using MRI or ex vivo on tissue and blood specimens: tumor growth, survival, cerebral perfusion, cellular density, tissue redox state, expression of tumor-associated NADH oxidase (tNOX) and transforming growth factor-beta 1 (TGF-β1). Dose-dependent effects of M/A on cell viability, mitochondrial functionality, and redox homeostasis were evaluated in vitro. M/A treatment suppressed tumor growth and significantly increased survival without adverse side effects. This was accompanied by increased oxidative stress, decreased reducing capacity, and decreased cellular density in the tumor only, as well as increased cerebral perfusion and down-regulation of tNOX and TGF-β1. M/A induced selective cytotoxicity and overproduction of mitochondrial superoxide in isolated glioblastoma cells, but not in normal microglial cells. This was accompanied by a significant decrease in the over-reduced state of cancer cells and impairment of their “pro-oncogenic” functionality, assessed by dose-dependent decreases in: NADH, NAD+, succinate, glutathione, cellular reducing capacity, mitochondrial potential, steady-state ATP, and tNOX expression. The safety of M/A on normal cells was compromised by treatment with cerivastatin, a non-specific prenyltransferase inhibitor. In conclusion, M/A differentiates glioblastoma cells and tissues from normal cells and tissues by redox targeting, causing severe oxidative stress only in the tumor. The mechanism is complex and most likely involves prenylation of menadione in normal cells, but not in cancer cells, modulation of the immune response, a decrease in drug resistance, and a potential role in sensitizing glioblastoma to conventional chemotherapy.Funding Information
- Japanese Agency for Medical Research and Development (AMED Grant Number 16cm0106202h, ICM/QST personal grant, Kakenhi #21H04966 and #17KK0102)
This publication has 132 references indexed in Scilit:
- Impact of Temozolomide on Immune Response during Malignant Glioma ChemotherapyJournal of Immunology Research, 2012
- Capsaicin-Mediated tNOX (ENOX2) Up-regulation Enhances Cell Proliferation and Migration in Vitro and in VivoJournal of Agricultural and Food Chemistry, 2012
- Vitamin K3 suppressed inflammatory and immune responses in a redox-dependent mannerFree Radical Research, 2011
- Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin CInvestigational New Drugs, 2010
- Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse EffectsPLOS ONE, 2010
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends in Immunology, 2010
- Down-regulation of TERE1/UBIAD1 activated Ras–MAPK signalling and induced cell proliferationCell Biology International Reports, 2010
- Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic studyInvestigational New Drugs, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Inhibition of the development of metastases by dietary vitamin C:K3 combinationLife Sciences, 2004